The Unlikely Duo Trying to Crack Pharma's Most Stubborn Locks
A Japanese biotech with molecular mimicry tricks teams up with an AI startup to go after "undruggable" protein targets, starting with obesity. Their bet: that smart chemistry plus smarter computation can crack what brute-force screening never could.
Some proteins are just rude. They sit inside your cells, cause disease, and refuse to interact with any drug you throw at them. Scientists call these "undruggable" targets, and they've been haunting pharma for decades.
Now a small Japanese biotech and an AI startup think they've found a way to pick the lock. PRISM BioLab and Receptor.AI just announced a strategic collaboration to combine their platforms and go after the targets that everyone else has struggled to hit. Their first mission: metabolic disease, including obesity.
It's the kind of partnership that sounds like a buzzword buffet at first glance. But dig into what each company actually brings, and there's a real logic here.
Why Most Drugs Can't Reach These Targets
To understand why this matters, you need to know about protein-protein interactions, or PPIs. Think of them as handshakes between proteins inside your cells. When those handshakes go wrong, diseases happen: cancer, fibrosis, metabolic disorders. The problem? Traditional small-molecule drugs are like trying to pry apart two clasped hands with a toothpick. The contact surfaces are too big, too flat, and too slippery.
Biologics (large, injectable proteins) can sometimes disrupt PPIs, but they can't get inside cells. That's the catch-22: small molecules can get in but can't grip the target; biologics can grip but can't get in.
PRISM BioLab has spent nearly two decades building a workaround.
PRISM's Secret Weapon: Molecular Mimicry
Founded in 2006 in Fujisawa, Japan, PRISM developed a proprietary chemistry platform called PepMetics®. The concept: build small molecules that are shaped like the key parts of proteins, specifically the twisted "alpha-helix" and looped "beta-turn" structures that proteins use when they shake hands with each other.
Imagine you're trying to break up a secret handshake. Instead of jamming your whole arm in there, you sculpt a tiny fake hand that mimics just the right grip. That's PepMetics. The molecules are rigid, three-dimensional, and designed to wedge into PPI surfaces. Crucially, they're small enough to be taken as a pill.
More from this issue
View full issue →
Clinical & Regulatory6 min read
The Pill That Wants to Kill the Needle in Psoriasis
J&J just got FDA approval for the first oral pill that rivals injectable biologics in clearing psoriasis. ICOTYDE beat the only other oral option head-to-head, and it's gunning for three more diseases next.
Clinical & Regulatory
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
